Date: 2011-04-11
Type of information:
phase: 2-3
Announcement: result of independent Data Monitoring Committee
Company: Merck&Co (USA) Intercell (Austria)
Product: V170
Action mechanism: investigational vaccine for the prevention of Staphylococcus aureus infection
Disease: Staphylococcus aureus infection
Therapeutic area: Infectious diseases
Country: USA
Trial details:
Latest news: Merck&Co and Intercell AG have announced that following a pre?specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment. Although the trial did not meet the pre?specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate. Merck and Intercell plan to provide a further update when analyses have been completed.
